GHO Capital Acquires Sterling Pharma Solutions
GHO Capital, a European specialist investor in healthcare, announced its acquisition of Sterling Pharma Solutions, which specializes in complex and difficult-to-manufacture APIs.
In a Feb. 28, 2019 press release, GHO Capital, a European specialist investor in healthcare, announced its acquisition of Sterling Pharma Solutions, which specializes in complex and difficult-to-manufacture APIs.
Kevin Cook, CEO of Sterling Pharma Solutions, commented, “We are delighted to partner with GHO Capital, whose expertise in the pharmaceuticals space and track record of supporting companies expand internationally will be invaluable in facilitating the next stage of our growth in Europe and in the United States.”
“Sterling provides a compelling opportunity to partner with a management team to support the global demand for complex chemistry in pharmaceuticals,” added Alan MacKay, partner at GHO Capital. “Sterling is today a leader in Europe from its United Kingdom operations and the plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.”
Sterling is headquartered in Newcastle-upon-Tyne, UK, and offers specialist services in API development and GMP manufacturing in order to support customers throughout the full product lifecycle.
Source: GHO Capital
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
